Giuseppe Rosiello1,2, Carlotta Palumbo3,4, Sophie Knipper3,5, Angela Pecoraro3,6, Stefano Luzzago3,7, Pierre-Antoine St-Hilaire3, Zhe Tian3, Umberto Capitanio8, Francesco Montorsi8, Shahrokh F Shariat9,10, Fred Saad3, Alberto Briganti8, Pierre I Karakiewicz3. 1. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. giusepperosiello@hotmail.it. 2. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. giusepperosiello@hotmail.it. 3. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. 4. Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. 5. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 6. Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy. 7. Department of Urology, European Institute of Oncology, Milan, Italy. 8. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. 9. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 10. Institute of Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Abstract
BACKGROUND: To compare survival outcomes of metastatic patients harbouring either papillary (pRCC) or clear-cell (ccRCC) renal cell carcinoma in overall population and according to treatment modality. METHODS: Within the Surveillance, Epidemiology and End Results database (2006-2015), we identified 6800 patients (585 papillary and 6215 clear-cell) with metastatic RCC. Propensity-score (PS) matching, Kaplan-Meier plots and multivariable Cox-regression models (CRMs) were used. RESULTS: Overall, 585 (8.6%) patients harboured pRCC. Rates of nodal metastases were higher in patients with pRCC (49.7 vs. 23.3%; p < 0.001). Median overall survival (OS) was 13 vs. 18 months for pRCC vs. ccRCC patients. After multivariable adjustments, no difference in OS was recorded. Furthermore, after propensity-score matching, virtually the same results were recorded. Median OS of pRCC vs. ccRCC was 8 vs. 4 months for no treatment (NT), 11 vs. 12 months for targeted therapy alone (TT), 17 vs. 35 months for cytoreductive nephrectomy alone (CN) and 18 vs. 25 months for combination of CN with TT. CONCLUSIONS: Metastatic pRCC patients exhibit poor survival, regardless of treatment received. Moreover, pRCC patients are more likely to present nodal metastases, compared to ccRCC patients, as demonstrated by twofold higher rates of lymph node invasion at diagnosis. These observations indicate that papillary variant represents more prognostically unfavorable tumor histology, in the context of metastatic RCC.
BACKGROUND: To compare survival outcomes of metastatic patients harbouring either papillary (pRCC) or clear-cell (ccRCC) renal cell carcinoma in overall population and according to treatment modality. METHODS: Within the Surveillance, Epidemiology and End Results database (2006-2015), we identified 6800 patients (585 papillary and 6215 clear-cell) with metastatic RCC. Propensity-score (PS) matching, Kaplan-Meier plots and multivariable Cox-regression models (CRMs) were used. RESULTS: Overall, 585 (8.6%) patients harboured pRCC. Rates of nodal metastases were higher in patients with pRCC (49.7 vs. 23.3%; p < 0.001). Median overall survival (OS) was 13 vs. 18 months for pRCC vs. ccRCC patients. After multivariable adjustments, no difference in OS was recorded. Furthermore, after propensity-score matching, virtually the same results were recorded. Median OS of pRCC vs. ccRCC was 8 vs. 4 months for no treatment (NT), 11 vs. 12 months for targeted therapy alone (TT), 17 vs. 35 months for cytoreductive nephrectomy alone (CN) and 18 vs. 25 months for combination of CN with TT. CONCLUSIONS: Metastatic pRCCpatients exhibit poor survival, regardless of treatment received. Moreover, pRCCpatients are more likely to present nodal metastases, compared to ccRCC patients, as demonstrated by twofold higher rates of lymph node invasion at diagnosis. These observations indicate that papillary variant represents more prognostically unfavorable tumor histology, in the context of metastatic RCC.
Authors: Bradley C Leibovich; Christine M Lohse; Paul L Crispen; Stephen A Boorjian; R Houston Thompson; Michael L Blute; John C Cheville Journal: J Urol Date: 2010-02-19 Impact factor: 7.450
Authors: Alessandro Larcher; Christopher J D Wallis; Axel Bex; Michael L Blute; Vincenzo Ficarra; Arnaud Mejean; Jose A Karam; Hendrik Van Poppel; Sumanta K Pal Journal: Eur Urol Oncol Date: 2019-05-18
Authors: Jean-Jacques Patard; Emmanuelle Leray; Nathalie Rioux-Leclercq; Luca Cindolo; Vincenzo Ficarra; Amnon Zisman; Alexandre De La Taille; Jacques Tostain; Walter Artibani; Claude C Abbou; Bernard Lobel; François Guillé; Dominique K Chopin; Peter F A Mulders; Christopher G Wood; David A Swanson; Robert A Figlin; Arie S Belldegrun; Allan J Pantuck Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: G Simone; G Tuderti; M Ferriero; R Papalia; L Misuraca; F Minisola; M Costantini; R Mastroianni; S Sentinelli; S Guaglianone; M Gallucci Journal: Eur J Surg Oncol Date: 2016-08-22 Impact factor: 4.424
Authors: Rodrigo A Ledezma; Edris Negron; Gladell P Paner; Chris Rjepaj; Danny Lascano; Mohammed Haseebuddin; Pankaj Dangle; Arieh L Shalhav; Henry Crist; Jay D Raman; G Joel DeCastro; Lara Harik; Monika Paroder; Robert G Uzzo; Alexander Kutikov; Scott E Eggener Journal: World J Urol Date: 2015-09-25 Impact factor: 4.226
Authors: John Connor Wells; Frede Donskov; Anna P Fraccon; Felice Pasini; Georg A Bjarnason; Benoit Beuselinck; Jennifer J Knox; Sun Young Rha; Neeraj Agarwal; Isaac Alex Bowman; Jae-Lyun Lee; Sumanta K Pal; Sandy Srinivas; Douglas Scott Ernst; Ulka N Vaishampayan; Lori A Wood; Robin Simpson; Guillermo De Velasco; Toni K Choueiri; Daniel Y C Heng Journal: Cancer Med Date: 2017-04-16 Impact factor: 4.452
Authors: Tao Wang; Yan Huang; Luojia Yang; Yang Yang; Di Li; Xiangyi Zhang; Xiaohui Ding; Baojun Wang; Xin Ma Journal: Front Oncol Date: 2022-09-05 Impact factor: 5.738